Skip to main content
Fig. 1 | Clinical Epigenetics

Fig. 1

From: BRCA loss of function including BRCA1 DNA-methylation, but not BRCA-unrelated homologous recombination deficiency, is associated with platinum hypersensitivity in high-grade ovarian cancer

Fig. 1

BRCA1 DNA-methylation in relation to BRCA-mutations, HRD and BRCA1 mRNA expression. (A) HRD-scores in different OC subgroups according to BRCA epigenetic or genetic aberrations (n = 120). HRD-score threshold was defined as ≥ 1.77 (red line). The HRD-scores above this threshold were considered HRD-positive (HR-deficient) and values below the threshold were considered HRD-negative (HR-proficient). Note: The BRCA2-mut-meth tumor is included in the BRCA-mut group. (B) BRCA1 mRNA expression in relation to BRCA1 epigenetic or genetic aberrations (n = 63) Note: BRCA2-mut tumors are included in the BRCA1-wt group, the BRCA2-mut-meth tumor is included in the BRCA1-meth group

Back to article page

Clinical Epigenetics

ISSN: 1868-7083

Contact us